Rural Generalist Anaesthetic Resource
  • Welcome
  • Curriculum
  • Curriculum
    • 1. RGA Roles
    • 2. RGA Clinical Fundamentals
      • 2.1 Airway Management
      • 2.2 General Anaesthesia and Sedation
      • 2.3 Pain Medicine
      • 2.4 Perioperative Medicine
      • 2.5 Regional and local anaesthesia
      • 2.6 Resuscitation, Trauma and Crisis Management
      • 2.7 Safety and Quality in Anaesthesia Practice
    • 3. Specialised Study Units
      • Paediatrics
      • Obstetric Anaesthesia and Analgesia
  • Exam Resources
    • Exam Resources
      • SSSA VIVA trainer
      • Unexamined VIVAs
  • Additional Notes
    • Lecture Notes
    • Study notes
      • Malignant Hyperthermia
    • Memory Aids
  • Miscellania
    • Useful stuff for RGAs
    • Spectacular Photos
  • About Us
    • Page
Powered by GitBook
On this page
  1. Additional Notes
  2. Study notes

Malignant Hyperthermia

๐Ÿ’ช Definition: Malignant Hyperthermia (MH) is a rare, life-threatening pharmacogenetic disorder of skeletal muscle, triggered by certain anaesthetic agents (volatile agents, suxamethonium), leading to uncontrolled intracellular calcium release and a hypermetabolic crisis.


๐Ÿชจ Triggers:

  • Volatile anaesthetic agents (e.g. sevoflurane, desflurane)

  • Succinylcholine (suxamethonium)

๐Ÿค” Pathophysiology:

  • Mutation in RYR1 (ryanodine receptor) gene โ†’ excess calcium release from sarcoplasmic reticulum

  • Sustained muscle contraction, ATP depletion, heat and lactic acid production

Clinical Features:

Feature
Notes

๐Ÿ”ข EtCOโ‚‚ โ†‘

Early sign; rises despite hyperventilation

๐ŸŒก๏ธ Hyperthermia

| Often a late sign

โค๏ธ Tachycardia

Often first cardiovascular sign

๐Ÿงฑ Muscle rigidity

Generalised or masseter spasm

๐Ÿ“‰ Acidosis

Metabolic ยฑ respiratory

โœจ Hyperkalaemia

May lead to arrhythmias

๐Ÿ’ณ Myoglobinuria

Risk of AKI

๐Ÿ“… CK โ†‘

Rhabdomyolysis marker


๐Ÿ“‰ Key Investigations:

  • Arterial blood gas (ABG): Acidosis, hyperkalaemia, lactate

  • CK, serum myoglobin, renal function

  • Core temperature

  • Urinalysis for pigment


๐Ÿ“… Management: Use "S.A.F.E.R."

Step
Action

๐Ÿ”ด S

Stop the trigger: Cease volatile agent/suxamethonium, remove vaporiser

๐Ÿช‚ A

Airway + 100% Oโ‚‚: Hyperventilate to clear COโ‚‚ and reduce acidosis

๐Ÿงช F

First-line therapy: Give Dantrolene 2.5 mg/kg IV, repeat q5-10 min (max 10 mg/kg)

๐Ÿ“ข E

Escalate: Call for help, delegate dantrolene prep (2 staff), notify retrieval/ICU early

๐Ÿš R

Rescue planning: Insert IDC, cool patient, monitor for complications, prep transfer

Supportive Measures:

  • Active cooling: IV cold fluids, ice packs, fan

  • Treat hyperkalaemia: Calcium chloride/gluconate, insulin + dextrose

  • Insert arterial line, urinary catheter

  • Serial monitoring: ABG, CK, renal function


๐Ÿฅ Post-Event Management:

  • Do NOT extubate early

  • ICU admission mandatory

  • Refer for confirmatory testing (e.g. caffeine halothane contracture test (CHCT) or genetic RYR1 testing)

  • Family screening + documentation


๐ŸŒ Scenarioville Context Considerations:

  • Check MH kit weekly (stock dantrolene and protocol)

  • At least 2 staff required for reconstituting traditional dantrolene (20 mg/vial)

  • Maintain up-to-date MH policy and liaise with centralised retrieval service early


๐Ÿ’ก Pro Tip for Viva:

"I would apply the SAFE-R mnemonic to structure my response, emphasise early dantrolene, team delegation, supportive care, and prompt ICU retrieval from Scenarioville."

PreviousStudy notesNextMemory Aids

Last updated 5 days ago